Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
- Published In:
- The Lancet. Infectious diseases, 4(7), 426-36 (2004)
- Authors:
- Cooper, David A, Lange, Joep M A
- Database ID:
- RPEP-00898
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00898APA
Cooper, David A; Lange, Joep M A. (2004). Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.. The Lancet. Infectious diseases, 4(7), 426-36.
MLA
Cooper, David A, et al. "Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.." The Lancet. Infectious diseases, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Peptide inhibitors of virus-cell fusion: enfuvirtide as a ca..." RPEP-00898. Retrieved from https://rethinkpeptides.com/research/cooper-2004-peptide-inhibitors-of-viruscell
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.